DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

EASI Access II --- Follow-up Study to the EASI Access Trial

Phase 1

Completed

Conditions: Disaster Medicine
Difficult Intravenous Access
Dehydration

Interventions: Drug: Human recombinant hyaluronidase (HRH)
Procedure: Enzymatically Augmented Subcutaneous Infusion (EASI) line placement

First Posted Date: 2008-08-25

Last Posted Date: 2009-09-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT00740727

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Cognitive Behavioral Therapy for Trichotillomania

Phase 1

Completed

Conditions: Trichotillomania

Interventions: Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2008-08-25

Last Posted Date: 2012-06-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 38

Registration Number: NCT00740909

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Diabetes Prevention Program

First Posted Date: 2008-08-20

Last Posted Date: 2013-07-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 15

Registration Number: NCT00738140

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Changes in Leukotrienes During Cardiac Surgery in Patients With Chronic Obstructive Pulmonary Disease

Completed

Conditions: Lung Dysfunction
Inflammatory Response During Cardiac Surgery

First Posted Date: 2008-08-14

Last Posted Date: 2013-03-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT00734266

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2008-08-11

Last Posted Date: 2013-12-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 81

Registration Number: NCT00731653

Locations: 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸
Synergy Research Centers, San Diego, California, United States
🇺🇸
Atlanta Institute of Medicine & Research, Inc., Altanta, Georgia, United States

and more 6 locations

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: RAD001
Drug: lenalidomide

First Posted Date: 2008-08-07

Last Posted Date: 2014-08-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00729638

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 2 locations

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

Phase 2

Terminated

Conditions: Hidradenitis Suppurativa

Interventions: Drug: drospirenone and ethinyl estradiol (YAZ)
Drug: Placebo

First Posted Date: 2008-07-28

Last Posted Date: 2014-02-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 4

Registration Number: NCT00722800

Locations: 🇺🇸
Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: drospirenone and ethinyl estradiol
Drug: Placebo tablet

First Posted Date: 2008-07-28

Last Posted Date: 2013-03-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00722761

Locations: 🇺🇸
Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States

Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: Avastin

First Posted Date: 2008-07-28

Last Posted Date: 2017-10-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT00722865

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa

Phase 2

Completed

Conditions: Disorder of Bone Density and Structure, Unspecified

Interventions: Drug: Recombinant human insulin like growth factor-1 (rhIGF-1)

First Posted Date: 2008-07-22

Last Posted Date: 2021-11-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00720122

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy